Trial reportInfluenza and other respiratory viruses2012
Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety.
Trial report in Influenza and other respiratory viruses, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Vaccinations in patients with interstitial lung diseases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- COVID-19 infection and pulmonary sarcoidosis: a systematic review and meta-analysis of morbidity, severity and mortality.Journal of thoracic disease · 2025Article
- Infectious Complications of Pulmonary Sarcoidosis.Journal of clinical medicine · 2024Review
- Humoral and Cellular Immunity to Severe Acute Respiratory Syndrome Coronavirus-2 Vaccination in Patients with SarcoidosisBalkan medical journal · 2023Article
- Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis.ERJ open research · 2023Article
- Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation.Biomedicines · 2022Review
- COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities.Frontiers in medicine · 2021Review
- Treatment of Sarcoidosis: A Multidisciplinary Approach.Frontiers in immunology · 2020Review
- Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020Review
- Immunologic Effects of the Renin-Angiotensin System.Journal of the American Society of Nephrology : JASN · 2017Review
- "Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?".Medical microbiology and immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. The role of cellular and humoral immune systems in this disease is unclear, whereas dysregulation of the immune system is suggested. Patients with sarcoidosis show diverse responses while exposed to various antigens. Although influenza vaccination is recommended in pulmonary sarcoidosis, its efficacy and safety has not been investigated.
objectivesTo evaluate safety and immunogenicity of influenza vaccine in patients with sarcoidosis. PATIENTS/
methodsInfluenza vaccination was performed in 23 eligible patients with sarcoidosis (SP) and 26 healthy controls (HC). Antibody titers against H1N1, H3N2, and B influenza virus antigens were evaluated just before and 1 month after vaccination. Patients were followed for 6 months to assess vaccine safety.
resultsSerological response and magnitude of changes in antibody titers against influenza vaccine antigens were comparable between SPs and HCs. Women showed a better serological response against B antigen (P = 0·034) than men. Twenty-four-hour urine calcium was associated with antibody response against H1N1 [correlation coefficient (CC) = 0·477, P = 0·003] and H3N2 (CC = 0·352, P = 0·028) antigens. Serum angiotensin-converting enzyme correlated negatively with antibody response against B antigen (CC = -0·331, P = 0·040). Higher residual volume was associated with fewer rises in antibody titer against H3N2 antigen (CC = -0·377, P = 0·035). No major adverse events or disease flare-up was observed during follow-up.
conclusionsIn this study, influenza vaccination did not cause any major adverse event in SPs, and their serological response was equal to HCs. Studies with larger sample size and a broader selection of subjects could help validate the results of this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.